VAXCYTE, INC. Net Change in Cash
VAXCYTE, INC. (PCVX) reported Net Change in Cash of $9.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-05
- VAXCYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $86.88M.
- VAXCYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$41.03M, a 119.17% decline year-over-year.
- VAXCYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $214.06M.
- VAXCYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$454.21M, a 442.14% decline year-over-year.
- VAXCYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$213.77M.
- VAXCYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$9.36M.
- VAXCYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$436.97M, a 157.07% decline from fiscal 2022.
- VAXCYTE, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $765.67M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.23M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $86.88M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$213.77M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | -$106.65M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | -$81.13M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | -$41.03M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$9.36M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $652.95M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $121.22M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $214.06M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$436.97M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | -$289.29M 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | -$303.62M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$454.21M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $765.67M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $209.42M 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | $169.19M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $132.76M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$316.34M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | -$273.29M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | -$234.33M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$186.39M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $327.22M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $338.07M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $351.07M 10-Q · filed 2021-08-11 | |||
| 2020-03-31 | $95.81M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$7.11M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | -$32.77M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$23.62M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $29.95M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |